What is Servatus?
Founded in 2012 and headquartered in Coolum Beach, Queensland, Australia, Servatus is a biotechnology firm focused on developing microbial-based therapeutics. The company is actively engaged in human clinical trials for several prospective treatments targeting debilitating autoimmune, inflammatory, gastrointestinal, and dermatological conditions. Servatus's commitment to alternative treatment modalities positions it within the rapidly evolving landscape of biopharmaceutical innovation.
How much funding has Servatus raised?
Servatus has raised a total of $7.5M across 1 funding round:
Unspecified
$7.5M
Unspecified (2021): $7.5M, investors not publicly disclosed
What's next for Servatus?
The recent major strategic investment provides Servatus with substantial capital to advance its pipeline of microbial-based drugs through critical clinical trial stages. This financing is expected to accelerate research and development efforts, potentially enabling the company to bring novel treatments for complex diseases to market. The enterprise-level funding context suggests a strategic push towards scaling operations and solidifying its market position in the biopharmaceutical sector.
See full Servatus company page
